Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Q3 2025 value amounting to $177.6 million.

  • Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) rose 1921.12% to $177.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.6 million, marking a year-over-year increase of 1921.12%. This contributed to the annual value of $146.8 million for FY2024, which is 660.83% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Shares Outstanding (Diluted Average) stood at $177.6 million for Q3 2025, which was up 1921.12% from $159.5 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' Shares Outstanding (Diluted Average)'s 5-year high stood at $177.6 million during Q3 2025, with a 5-year trough of $61.2 million in Q1 2021.
  • For the 5-year period, Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) averaged around $128.4 million, with its median value being $137.3 million (2023).
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) skyrocketed by 12047.89% in 2022, and later skyrocketed by 133.41% in 2023.
  • Xeris Biopharma Holdings' Shares Outstanding (Diluted Average) (Quarter) stood at $79.0 million in 2021, then skyrocketed by 71.62% to $135.6 million in 2022, then rose by 1.51% to $137.7 million in 2023, then increased by 6.61% to $146.8 million in 2024, then grew by 21.02% to $177.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $177.6 million for Q3 2025, versus $159.5 million for Q2 2025 and $152.4 million for Q1 2025.